RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induced hemoconcentration and TNF release

J Lipid Mediat. 1989 Nov-Dec;1(6):349-60.

Abstract

Platelet-activating factor (PAF) and tumor necrosis factor (TNF) are present in the plasma of animals injected with endotoxin (LPS). Furthermore, when exogenously administered to animals, PAF and TNF induce similar pathological effects. Thus, in order to explore a possible link between these two factors, the effects of a PAF receptor antagonist, RP 55778, and a glucocorticoid, dexamethasone, were studied on LPS-induced hemoconcentration in rats and on the release of TNF induced by exposing isolated murine macrophages to LPS. RP55778 administered either before or after LPS inhibited these endotoxin effects whereas dexamethasone was effective only when given prior to the LPS challenge. Additionally, in murine macrophages the strong TNF mRNA signal induced by LPS was abolished by RP 55778 and dexamethasone treatment. These results indicate that PAF and TNF can mediate the functional manifestations associated with endotoxemia and only RP 55778 appears to show potential for activity against an already established LPS response.

MeSH terms

  • Animals
  • Blood Volume / drug effects*
  • Dexamethasone / pharmacology
  • In Vitro Techniques
  • Lipopolysaccharides / toxicity
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Male
  • Mice
  • Platelet Activating Factor / antagonists & inhibitors*
  • Pyridines / pharmacology*
  • RNA, Messenger / metabolism
  • Rats
  • Thiazoles / pharmacology*
  • Tumor Necrosis Factor-alpha / drug effects*

Substances

  • Lipopolysaccharides
  • Platelet Activating Factor
  • Pyridines
  • RNA, Messenger
  • Thiazoles
  • Tumor Necrosis Factor-alpha
  • Dexamethasone
  • 3-(3-pyridinyl)-1H,3H-pyrrolo(1,2-c)thiazole-7-carboxamide